<DOC>
	<DOC>NCT01740934</DOC>
	<brief_summary>This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>age between 2570 years diagnosed with mild to moderate rosacea allergy or sensitivity to the study products or their components severe rosacea current use of glucocorticoids, antiacne products, antibiotics, topical retinoids, or vasoactive drugs recent oral isotretinoin use current use of anatabinecontaining supplements (ie. Anatabloc, Anatabloc Unflavored, CigRx)</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>rosacea</keyword>
	<keyword>anatabine</keyword>
	<keyword>Anatabloc</keyword>
	<keyword>dermatology</keyword>
</DOC>